UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000030955
Receipt number R000034447
Scientific Title Pembrolizumab as first-line therapy in poor performance status patients with advanced non-small-cell lung cancer highly expressing PD-L1: an open-label, single arm, multicenter, phase II study
Date of disclosure of the study information 2018/04/01
Last modified on 2022/07/28 20:40:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Pembrolizumab as first-line therapy in poor performance status patients with advanced non-small-cell lung cancer highly expressing PD-L1: an open-label, single arm, multicenter, phase II study

Acronym

Pembrolizumab in poor performance status patients

Scientific Title

Pembrolizumab as first-line therapy in poor performance status patients with advanced non-small-cell lung cancer highly expressing PD-L1: an open-label, single arm, multicenter, phase II study

Scientific Title:Acronym

Pembrolizumab in poor performance status patients

Region

Japan


Condition

Condition

advanced non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

efficacy of pembrolizumab in patients with NSCLC expressing high PD-L1

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

objective response rate

Key secondary outcomes

progression free survival
overall survival
safety
quality of life
explore possible biomarkers


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

treatment with pembrolizumab

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) age of 20 years or older
2) histologically or cytologically proven non-small cell cancer
3) stage IV, incurable stage IIIB/C, or postoperative recurrent disease
4) treatment naive for lung cancer
5) PD-L1 (TPS = or > 50%)
6) without EGFR mutation or ALK fusion
7) without ROS1 fusion or unknown
8) an Eastern Cooperative Oncology Group performance status of 2 to 3
9) presence of a measurable lesion (RECIST ver. 1.1)
10) without uncontrolled severe comorbidities including pleural effusion, ascites and pericardial effusion, SVC symdrome, or spinal cord compression
11) without a history of palliative radiation therapy within 7 days of registration
12) adequate organ function
13) written informed consent

Key exclusion criteria

1) comordity of auto-immune disease
2) history of organ transplantation
3) symptomatic brain metastasis
(patients with stable condition for more than 7days after radiation will be allowed.)
4) carcinomatous meningitis
5) presence of other cancer within 2 years of registration
6) presence of severe comordity

Target sample size

14


Research contact person

Name of lead principal investigator

1st name Katsuyuki
Middle name
Last name Kiura

Organization

Okayama University Hospital

Division name

Allergy and respiratory medicine

Zip code

700-8558

Address

2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

TEL

086-235-7227

Email

kkiura@md.okayama-u.ac.jp


Public contact

Name of contact person

1st name Eiki
Middle name
Last name Ichihara

Organization

Okayama University Hospital

Division name

Allergy and respiratory medicine

Zip code

700-8558

Address

+81-86-235-7227

TEL

086-235-7227

Homepage URL


Email

ichiha-e@md.okayama-u.ac.jp


Sponsor or person

Institute

Department of allergy and respiratory medicine
Okayama University Hospital

Institute

Department

Personal name



Funding Source

Organization

Department of allergy and respiratory medicine
Okayama University Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Okayama University Hospital Ethics Comittee

Address

2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

Tel

086-235-6938

Email

mae6605@adm.okayama-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

14

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2017 Year 11 Month 28 Day

Date of IRB

2018 Year 02 Month 20 Day

Anticipated trial start date

2018 Year 01 Month 17 Day

Last follow-up date

2023 Year 09 Month 03 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 01 Month 23 Day

Last modified on

2022 Year 07 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034447


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name